Trials / Unknown
UnknownNCT05057065
A Clinical Research on Disease Progression and Intervention of Chronic HepatitisB
Disease Progression and Intervention of Chronic HepatitisB Based on Diabetes and Hyperlipidemia
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 10,000 (estimated)
- Sponsor
- Hong Ren · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
HBV(hepatitis B virus) with metabolic comorbidities may accelerate liver disease progression and increase the risk of HCC(Hepatocellular Carcinoma)development. It is reported combination of metabolic diseases and CHB is associated with substantially increased rates of liver cirrhosis and secondary liver-related events compared to CHB alone. Consequently, hepatitis B patients with metabolic comorbidities warrant particular attention in disease surveillance and evaluation of treatment indications.
Detailed description
Primary objective: To evaluate the impact of metabolic disease on the progression of chronic hepatitis B * To observe HBsAg/HBeAg/HBV DNA changes /HBsAg seroconversion * To determine high rates of Liver Cirrhosis and Hepatocellular Carcinoma Group 1 : CHB with diabetes Group 2 : CHB with hyperlipemia Group 3 : CHB without metabolic diseases Study Duration (in months) 24 months
Conditions
Timeline
- Start date
- 2021-09-15
- Primary completion
- 2022-09-01
- Completion
- 2023-06-01
- First posted
- 2021-09-27
- Last updated
- 2021-09-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05057065. Inclusion in this directory is not an endorsement.